One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
INmune Bio logo
INmune Bio INMB
$ 0.82 -7.87%
report update icon

Quarterly report 2026-Q3
added 11-05-2026

INmune Bio Income Statement 2025-2011 | INMB

Brief overview of income trends at INmune Bio

The figures are compared over a five-year interval. INmune Bio reported revenue of $10.9 thousand in 2020 and $50 thousand by 2025. Overall revenue changed by +358%, equal to an annualized rate of about 35.6%. The company expanded its revenue base at a high speed.

EBITDA was −12.2 million dollars at the beginning and −47.3 million dollars at the end of the period (−286.8%). Operating performance weakened relative to revenue. The EBITDA share of revenue changed from −112016.1% to −94598%. The increased EBITDA share is a positive sign.

Net income moved from −12.1 million dollars at the start to −46 million dollars at the end. The negative result deepened, showing weaker final efficiency.

The five-year change in capitalization reached −88%: from $236 million to $28.2 million. The market has not yet confirmed the improvement in fundamentals.

Financial takeaway

The financial trajectory is weak and requires a cautious interpretation. The constructive conclusion rests on revenue expansion and an improving EBITDA margin. Caution is warranted because of declining net profitability, limited operating profitability and lower investor confidence. The key question is whether sales can be converted into sustainable profit.

Annual Income Statement INmune Bio

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

28.2 M 22.7 M 211 M 166 M 163 M 236 M 49.1 M - - - - - - - -

Shares

24.8 M 19.9 M 18 M 17.9 M 16.1 M 12.9 M 10.3 M 8.68 M 6.56 M - - - - - -

Historical Prices

1.14 1.14 11.8 9.25 10.1 18.2 4.93 - - - - - - - -

Net Income

-46 M -42 M -30 M -27.3 M -30.3 M -12.1 M -7.68 M -12.4 M -831 K -277 K - - - - -

Revenue

50 K 14 K 155 K 374 K 181 K 10.9 K - - - - - - - - -

Gross Profit

- - - - - -10.9 K - - - - - - - - -

Operating Income

-47.4 M -42.6 M -29.7 M -26 M -29.2 M -12.2 M -7.76 M -12.4 M -981 K - - - - - -

Interest Expense

- 789 K 2.28 M 2.01 M - 129 K 77.7 K - 150 K - - - - - -

EBITDA

-47.3 M -42.6 M -29.7 M -26 M -29.2 M -12.2 M -10.8 M -12.4 M -981 K -177 K - - - - -

Operating Expenses

47.4 M 42.6 M 29.9 M 26.3 M 29.3 M 12.2 M 9.3 M 12.4 M 981 K - - - - - -

General and Administrative Expenses

10.3 M 9.48 M 9.62 M 9.26 M 8.79 M 6.32 M 6.02 M 9.09 M 546 K 126 K - - - - -

All numbers in USD currency

Quarterly Income Statement INmune Bio

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

27.8 M 26.7 M 26.6 M 616 K 26.6 M 23.3 M 22.5 M 767 K 20.2 M 19.3 M 18 M 13.8 M 18 M 17.9 M 17.9 M 6.29 M 17.9 M 17.9 M 17.9 M 577 K 17.3 M 15 M 14.3 M 492 K 12.9 M 10.8 M 10.7 M 167 K 10.8 M 10.2 M 9.39 M 8.72 M 8.72 M 8.72 M 8.55 M 8.32 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-4.72 M -1.27 M -5.41 M -5.26 M -6.47 M -24.5 M -9.74 M -9.22 M -12.1 M -9.75 M -11 M -8.41 M -8.56 M -6.5 M -6.54 M - -7.72 M -6.84 M -6.9 M -9.67 M -9.46 M -6.66 M -4.56 M -3.2 M -4.72 M -2.11 M -2.07 M -2.32 M -3.07 M -392 K -1.9 M - -1.54 M -6.17 M -2.85 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- 50 K 50 K - 50 K - 50 K - - - 14 K 28 K 43 K 46 K 38 K 97 K 98 K 16 K 163 K 163 K 14 K - 4 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-5.01 M -1.48 M -5.81 M -5.47 M -7.43 M -24.6 M -9.9 M -9.47 M -12.3 M -9.86 M -11 M -8.38 M -8.53 M -6.41 M -6.42 M -5.64 M -7.44 M -6.39 M -6.48 M -9.03 M -9.02 M -6.55 M -4.55 M -3.21 M -4.82 M -2.11 M -2.09 M -2.33 M -3.08 M -428 K -1.91 M - -1.54 M -6.17 M -2.85 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- - - - - - 166 K - 145 K 250 K -8 K -2.08 M 568 K 631 K 612 K - - - - - - - -8 K 4.57 K 102 K -395 22 K 14.1 K 17.2 K 36.3 K 10 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-4.91 M -1.38 M -5.76 M -5.42 M -7.4 M -24.6 M -9.9 M -9.47 M -12.3 M -9.86 M -11 M -8.38 M -8.53 M -6.41 M -6.42 M -5.64 M -7.44 M -6.39 M -6.48 M -9.03 M -9.02 M -6.55 M -4.55 M -3.21 M -4.82 M -2.11 M -2.09 M -2.33 M -3.08 M -428 K -1.91 M - -1.54 M -6.17 M -2.85 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

5.01 M 1.48 M 5.81 M 5.47 M 7.43 M 24.6 M 9.96 M 9.47 M 12.3 M 9.86 M 11 M 8.41 M 8.57 M 6.46 M 6.46 M 5.74 M 7.54 M 6.4 M 6.64 M 9.19 M 9.04 M 6.55 M 4.55 M 3.22 M 4.82 M 2.11 M 2.09 M 2.33 M 3.08 M 428 K 1.91 M - 1.54 M 6.17 M 2.85 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

1.85 M 2.28 M 2.17 M 3.14 M 2.55 M 2.25 M 2.32 M 2.11 M 2.22 M 2.81 M 2.34 M 2.4 M 2.59 M 2.31 M 2.33 M 2.33 M 2.38 M 2.22 M 2.33 M 2.12 M 2.52 M 2.09 M 2.06 M 1.36 M 2.46 M 1.2 M 1.3 M 1.47 M 1.92 M 1.34 M 1.3 M - 885 K 5.89 M 2.74 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company INmune Bio (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
NexImmune NexImmune
NEXI
- 70.13 % $ 4.12 M usaUSA
Theravance Biopharma Theravance Biopharma
TBPH
$ 17.03 0.03 % $ 857 M cayman-islandsCayman-islands
Nuvation Bio Nuvation Bio
NUVB
$ 3.79 -0.52 % $ 1.29 B usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
LogicBio Therapeutics LogicBio Therapeutics
LOGC
- - $ 229 M usaUSA
AbbVie AbbVie
ABBV
$ 286.15 0.94 % $ 506 B usaUSA
89bio 89bio
ETNB
- - $ 1.55 B usaUSA
Harpoon Therapeutics Harpoon Therapeutics
HARP
- - $ 763 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 143.74 -2.76 % $ 18.8 B usaUSA
Amgen Amgen
AMGN
$ 435.4 -0.21 % $ 234 B usaUSA
RedHill Biopharma Ltd. RedHill Biopharma Ltd.
RDHL
$ 0.29 -11.35 % $ 3.57 B israelIsrael
Seagen Seagen
SGEN
- - $ 42.2 B usaUSA
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Zosano Pharma Corporation Zosano Pharma Corporation
ZSAN
- 7.23 % $ 2.72 M usaUSA
Spectrum Pharmaceuticals Spectrum Pharmaceuticals
SPPI
- - $ 189 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Kaleido Biosciences Kaleido Biosciences
KLDO
- -3.69 % $ 12.4 M usaUSA
VBI Vaccines VBI Vaccines
VBIV
- -50.87 % $ 1.09 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
Decibel Therapeutics Decibel Therapeutics
DBTX
- - $ 123 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 26.35 -3.02 % $ 3.35 B usaUSA
IVERIC bio IVERIC bio
ISEE
- - $ 5.51 B usaUSA
ObsEva SA ObsEva SA
OBSV
- -15.52 % $ 10.5 M schweizSchweiz
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 41.53 -4.86 % $ 5.88 B usaUSA
Monopar Therapeutics Monopar Therapeutics
MNPR
$ 69.02 -1.81 % $ 512 M usaUSA
Poseida Therapeutics Poseida Therapeutics
PSTX
- - $ 857 M usaUSA
Y-mAbs Therapeutics Y-mAbs Therapeutics
YMAB
- - $ 382 M usaUSA
Satsuma Pharmaceuticals Satsuma Pharmaceuticals
STSA
- -0.9 % $ 36.5 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
$ 0.59 -11.3 % $ 50.3 M usaUSA
SpringWorks Therapeutics SpringWorks Therapeutics
SWTX
- - $ 3.48 B usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 291.02 -5.2 % $ 22.7 B usaUSA
Infinity Pharmaceuticals Infinity Pharmaceuticals
INFI
- -46.98 % $ 3.57 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Evelo Biosciences Evelo Biosciences
EVLO
- -14.46 % $ 27.9 M usaUSA
Morphic Holding Morphic Holding
MORF
- - $ 2.42 B usaUSA
Genocea Biosciences Genocea Biosciences
GNCA
- -15.0 % $ 3.04 M usaUSA
Biogen Biogen
BIIB
$ 249.55 0.98 % $ 36.6 B usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 58.74 0.69 % $ 119 B usaUSA
Eiger BioPharmaceuticals Eiger BioPharmaceuticals
EIGR
- -9.21 % $ 2.55 M usaUSA
IGM Biosciences IGM Biosciences
IGMS
- - $ 76.9 M usaUSA
Merrimack Pharmaceuticals Merrimack Pharmaceuticals
MACK
- - $ 216 M usaUSA
Rubius Therapeutics Rubius Therapeutics
RUBY
- -33.55 % $ 7.81 M usaUSA
Mirati Therapeutics Mirati Therapeutics
MRTX
- - $ 3.3 B usaUSA
InVivo Therapeutics Holdings Corp. InVivo Therapeutics Holdings Corp.
NVIV
- -37.48 % $ 476 K usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
- 1.02 % $ 90.8 M britainBritain